辅助度伐利尤单抗启动时机与III期非小细胞肺癌结局无关
该回顾性队列利用美国退伍军人健康管理局数据库纳入728例接受根治性放化疗后120天内启动度伐利尤单抗的III期非小细胞肺癌患者,中位启动时间为41天。多变量Cox回归显示,放疗结束至度伐利尤单抗启动时间与无进展生存期(aHR 1.01/周,95%CI 0.98-1.04,P=0.4)和总生存期(aHR 1.02/周,95%CI 0.98-1.06,P=0.3)均无关。
要点
- 放疗结束至度伐利尤单抗启动的中位时间为41天(四分位距30-58天)。
- 启动时间每延迟一周,PFS的aHR为1.01(95%CI 0.98-1.04,P=0.4),OS的aHR为1.02(95%CI 0.98-1.06,P=0.3)。
- 放疗后≤14天启动度伐利尤单抗同样未改善PFS或OS。
核心结论
- 在放疗完成后120天内启动度伐利尤单抗,其启动时机与真实世界III期非小细胞肺癌患者的无进展生存期和总生存期均无关。
研究设计与样本
- 利用美国退伍军人健康管理局数据库进行的回顾性研究,纳入728例接受根治性放化疗并在放疗完成后120天内启动度伐利尤单抗的III期非小细胞肺癌患者。
- 采用多变量Cox回归模型分析放疗末次治疗至首次度伐利尤单抗输注的时间与无进展生存期和总生存期的关系,并校正基线患者和疾病特征。
- 主要分析采用120天界标法,从放疗完成后120天起计算总生存期和无进展生存期。
主要发现
- 728例患者中,放疗结束至度伐利尤单抗启动的中位时间为41天(四分位距30-58天)。
- 多变量Cox回归显示,放疗结束至度伐利尤单抗启动时间与无进展生存期无关(校正风险比[aHR] 1.01/周,95%置信区间[CI] 0.98-1.04,P=0.4)。
- 多变量Cox回归显示,放疗结束至度伐利尤单抗启动时间与总生存期无关(aHR 1.02/周,95%CI 0.98-1.06,P=0.3)。
- 放疗后≤14天启动度伐利尤单抗同样与无进展生存期或总生存期改善无关。
- 采用不同分析技术的敏感性分析结果稳健。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: It is unclear whether time from radiation therapy (RT) completion to durvalumab initiation influences the outcomes of stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation and adjuvant durvalumab. METHODS AND MATERIALS: Using the US Veterans Health Administration database, we retrospectively identified 728 patients with stage III NSCLC treated with definitive chemoradiation who started durvalumab within 120 days of radiation completion. Time between the last radiation treatment and first durvalumab infusion was analyzed in multivariable Cox regression models for the primary outcomes of progression-free survival (PFS) and overall survival (OS), adjusting for baseline patient and disease characteristics. The primary analysis used a 120-day landmark, measuring OS and PFS from 120 days after radiation completion. RESULTS: Among 728 patients, the median time from RT completion to durvalumab start was 41 days (interquartile range 30-58). In multivariable Cox regression, time from RT completion to durvalumab start showed no association with PFS (adjusted hazard ratio [aHR] 1.01 per week, 95% confidence interval [CI] 0.98-1.04, P = .4) or OS (aHR 1.02 per week, 95% CI 0.98-1.06, P = .3). Starting durvalumab ≤14 days after RT was also not associated with improved PFS or OS. Results were robust in sensitivity analyses varying analytical technique. CONCLUSIONS: Timing of durvalumab initiation up to 120 days after RT completion is not associated with PFS or OS in this real-world patient cohort.
引用
- Bryant AK, Sankar K, Strohbehn GW, et al. Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 35115216. doi:10.1016/j.ijrobp.2021.12.176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。